Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million

Kos Biotechnology Partners has announced the third closing of its inaugural global life sciences fund, successfully raising a total of $123 million in capital commitments. This milestone was achieved with backing from a syndicate of prominent institutional investors, including the lead investor Hellenic Development Bank of Investments (HDBI), as well as global family offices. The announcement was made on June 13, 2026, marking a significant achievement in the venture capital landscape of Greece.

Kos Biotechnology Partners is notable for being the first life sciences-dedicated investment fund in Greece, and its launch represents the largest venture capital fund initiation in the country’s history. The firm aims to bridge the US biopharma ecosystem with Europe, targeting high-impact investments across three core subsectors: biotech and novel therapeutics, pharma services, and tech-enabled technologies. The fund's investment strategy is designed to deploy capital flexibly across all stages of company development, from formation through Series C funding.

The founding team of Kos, comprising Dr. Simos Simeonidis and Alex Tzoukas, combines extensive experience in both finance and life sciences. Dr. Simeonidis brings a strong biomedical background from prestigious institutions such as Columbia and Harvard, along with over a decade of experience in biotechnology analysis at major investment banks. Tzoukas contributes over ten years of investment banking and private equity expertise in the healthcare sector. Together, they envision building a robust life sciences ecosystem in Greece, leveraging their deep networks and industry knowledge.

Kos Biotechnology Partners is already demonstrating operational momentum, having completed its first two investments shortly after the fund's launch. This includes a leading role in a financing round for Epikast, a tech-enabled pharma services provider, and a strategic investment in a San Francisco-based biotechnology company that is set to be announced soon. The firm’s ability to attract significant capital in a short timeframe underscores the growing interest in life sciences investments, particularly as the sector continues to evolve with advancements in technology and scientific research.

The successful fundraising by Kos Biotechnology Partners reflects broader trends in the life sciences sector, where innovative solutions and technologies are increasingly in demand. The convergence of biology, data science, and advanced computing is creating new opportunities to address complex health challenges. As the firm continues to invest in transformative companies, it is well-positioned to capitalize on the expanding life sciences ecosystem in Europe, while simultaneously fostering connections with the established biopharma expertise in the United States. This strategic positioning may serve to enhance the competitive landscape for life sciences investments in the region, signaling a promising outlook for future growth.